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Introduction
Improvements in the prevention of Tuberculosis (TB) remain 
an urgent global public health priority, with the disease killing 
an estimated 1.5 million people annually1. This high burden of 
mortality persists despite the long-term availability of the bacil-
lus Calmette-Guérin (BCG) vaccine, whose efficacy has been 
highly variable across populations. Recent trials of the vaccine 
candidate MVA85A, designed to boost BCG efficacy, showed 
high levels of immunogenicity in UK adults but poor levels in 
South African infants, highlighting a frustrating but common 
inconsistency of responses across populations2,3. This inconsistency 
of response is not limited to TB vaccines but is also observed in 
malaria and HIV vaccine development, where vaccine candidates 
often appear highly effective in early phase trials and yet perform 
below expectation in efficacy trials4. Calls to solve the puzzle of 
heterogeneous response to TB vaccination have traditionally 
focused on the technology of vaccine design and the interaction 
of Mycobacterium tuberculosis (M.tb) with the immune system 
at the molecular level5,6. These are crucial areas of investigation, 
but we argue that such large gaps in translation from the labora-
tory to human populations require new approaches to understand 
how social and biological variables interact to shape immune 
response and vaccine efficacy.
While research on both the social and biological determinants 
of TB risk is well developed, thus far the two lines of enquiry 
have proceeded largely independently. The social epidemiol-
ogy of TB typically examines social determinants of risk for 
exposure, diagnosis, and treatment, such as malnutrition, poor ven-
tilation and overcrowding, and barriers in access to health care7. 
The more limited literature on social factors and TB vaccination 
focuses on factors such as vaccine distribution and uptake, but not 
immune response or vaccine efficacy8, and does not attempt to 
understand how social determinants may influence the expression 
of biological markers relevant to BCG efficacy and risk of TB 
disease. To date, variability in BCG efficacy remains explained 
in terms of interference from previous exposure to tuberculous or 
non-tuberculous mycobacteria6. Meanwhile outside of the con-
text of TB, psychosocial and social influences on host immunity 
have been well described9–11, but research on socio-environmental 
factors and the biology of TB vaccine response is lacking.
In this paper, after providing an overview of the immune path-
ways important for the establishment of a response to the BCG 
vaccine, we propose a new focus on social determinants and 
psychosocial stressors that can contribute to the observed varia-
tion in BCG efficacy above and beyond these biological factors. 
We conclude by proposing a new interdisciplinary research model 
based on the integration of social epidemiology theories with 
biomedical knowledge.
BCG immune response and vaccine efficacy
While TB disease is a classic example of a disease of poverty, it 
is ultimately the failure of the immune system to contain infec-
tion which leads to active disease. Although we do not have a vali-
dated immune correlate of BCG vaccine efficacy, we know from 
studies of host-genetic susceptibility that cellular immunity plays 
a critical role in protection from TB disease12. Defects in the 
IFN-γ and IL-12 pathways, T cell and NK cell defects (GATA2 
deficiency) and defects in monocytes and dendritic cells (IRF8 
deficiency and CGD) are associated with susceptibility to myco-
bacterial disease12. Vaccination with BCG leads to the expansion 
of both classical antigen specific CD4+ and CD8+ T cells and 
non-classical cells such as CD1 and HLA-E restricted T cells13. 
There is also an NK response following immunization with 
BCG, likely driven by IL-2 secretion from mycobacterial anti-
gen specific CD4+ T cells14. BCG can modify the innate immune 
response through induction of epigenetic changes in monocytes 
and dendritic cells15. A role for BCG vaccine induced IFN-γ in 
protection from TB disease has been suggested in an infant study 
where both BCG-specific IFN-γ secretion and Ag85A specific 
IgG were associated with lower risk of developing TB disease14. 
The BCG vaccine can therefore interact and modify all the key 
immune cells and pathways identified in human genetic studies 
to be critical for protection from TB disease. 
Recently, specific correlates of immune risk for TB disease have 
been identified in BCG vaccinated infants aged 10 weeks16 and 
6 months14 enrolled in TB vaccine efficacy trials in the West-
ern Cape of South Africa. Immune markers associated with TB 
risk include CD4+ T cell activation14, increased monocyte to 
lymphocyte ratio16,17 CMV positivity on ELISPOT18, and Type I 
Interferon19. These immune correlates highlight a role for the host 
immune environment in TB disease risk. Pre-vaccination inflam-
mation has been associated with lower efficacy of hepatitis B, 
yellow fever and HIV vaccines20–22. Inflammation has also been 
associated with altered CD4 T cell response following immuniza-
tion with BCG23. Known environmental drivers of T cell activa-
tion include viral infection24,25, previous exposure to mycobacteria, 
age and proximity to the equator. However, there are also well- 
documented social and psychosocial determinants of these 
immune biomarkers in other contexts, which we describe below.
The role of socioeconomic and psychosocial factors 
on immunity
Socioeconomically disadvantaged populations face both mate-
rial and psychosocial threats to adequate host immunity9–11. 
Stress is defined as an event or environmental demand that 
exceeds an individual’s perceived ability to cope, eliciting physi-
ological stress responses from the hypothalamic-pituitary-adre-
nal (HPA) axis and the autonomic nervous system to deal with 
the threat26. There is abundant evidence from developed coun-
tries that chronic stressors and negative emotions such as anxiety 
and depression directly influence the immune system, including 
greater susceptibility to viral and bacterial infection and inhibited 
response to vaccines9,27,28. These stressors have also been found 
to be associated with other biomarkers of immunity and inflam-
mation including TNFA, IL6 and IL1B, decreased NK cell func-
tion, as well as impaired control over latent viral infections9,11,29–31. 
Increased monocyte counts and monocyte to lymphocyte ratios 
have also been found in individuals with depressive symptoms, a 
common consequence of chronic stress and social deprivation32,33. 
Importantly for vaccination of infants, prenatal maternal stress 
has been shown to influence postnatal immunity in offspring, 
though this literature is currently more developed in animals than 
in humans34,35. Despite the high burden of deprivation and 
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psychosocial stressors in areas where TB is endemic, the links 
between these exposures and biological immune response 
to BCG vaccine has not been explored. 
These important but seldom overlapping literatures present a 
unique opportunity to elucidate how the social environment 
contributes biologically to variability in BCG vaccine effi-
cacy. As an example of potential insights from such intersec-
tion, infection and immune response to one latent herpesvi-
rus, cytomegalovirus (CMV), has been associated with both 
socioeconomic status and stress in developed countries11,36. Recent 
work suggests that CD4+ T cell activation is associated with risk of 
TB in BCG vaccinated infants in South Africa, with CMV infec-
tion emerging as one important driver of this T-cell activation14. 
These associations suggest a testable pathway from socioeco-
nomic status and maternal stress, CMV reactivation, and impaired 
immune response to BCG vaccine in infants37,38. 
New opportunities for TB prevention: a “social 
technology” approach
From the pathway above, it could be argued that poverty reduc-
tion strategies, such as social protection, directly impacting 
socioeconomic status and maternal mental health could poten-
tially play a role in increasing BCG efficacy. Social protec-
tion has been defined as a range of policies that enable people 
to cope with and recover from shocks, with the objective of 
moving people out of extreme poverty and interrupting the trans-
generational transmission of inequalities39. Social protection 
includes widely used poverty-reduction strategies in both low and 
middle-income countries and encompasses both social secu-
rity and social assistance interventions. In the latter group, 
cash transfer interventions are currently the most popular form 
of social protection40. These typically consist of the provision 
of regular, non-contributory, monetary benefits to households 
living in poverty and extreme poverty. They can be given uncon-
ditionally or conditionally on a number of educational (i.e. 
children school enrollment and attendance) and health behav-
iour requirements (i.e. access to maternal and child care serv-
ices) that beneficiaries have to meet in order to remain enrolled. 
Today it is well acknowledged that cash transfers can improve 
beneficiaries’ socioeconomic status41. More recent literature 
suggests that cash transfers can significantly improve mater-
nal mental health42,43 as well as self-perceived happiness among 
beneficiaries44,45, pointing to potential benefits on biological 
markers of stress and immunity.
Based on these promising links, we call for the establishment 
of an interdisciplinary partnership, preliminarily named the 
“Social Technology Lab”, aiming to address the knowledge gaps 
in the pathways linking social protection, BCG immunologi-
cal response, and TB disease. The ultimate goal of this research 
effort is the development and testing of a new vaccine R&D model 
based on the combination of innovative biotechnology tools with 
poverty reduction strategies, using BCG as proof of concept. 
We argue that such an innovative paradigm can provide crucial 
insights into how social factors manifest biologically via immune 
response to TB vaccine and potentially help explain the puzzle 
of wide variation in responses. Ultimately, this interdisciplinary 
approach will increase our understanding of how social determi-
nants influence host immunity and TB risk over the life course, 
informing the integration of upstream structural and downstream 
biomedical intervention strategies. 
Conclusions
A more effective TB vaccine is considered the real game changer 
in the fight against the disease, however the development and 
delivery of new products may take decades even with consider-
able scientific and financial investment. Recent simulations sug-
gest that if existing biomedical tools, including current BCG, were 
combined synergistically with social protection interventions, 
this could result in a significant acceleration in the decline of TB 
incidence globally46. Innovative and alternative approaches to 
TB prevention are urgently needed while optimal biomedi-
cal tools continue to be developed. An interdisciplinary model 
that expands and integrates our understanding of how social 
determinants influence the biological processes that lead to TB 
disease, how this translates into differential BCG efficacy and, 
ultimately, how this influence can be affected by social protection 
interventions holds promise for reducing the global burden of TB 
disease.
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